Comparing Everolimus vs Lanreotide
| Everolimus | Lanreotide |
|
|---|
| Everolimus | Lanreotide |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Neuroendocrine Carcinoma, Breast Cancer, Renal Angiomyolipoma, Tuberous Sclerosis Complex, Brain Tumor, Organ Transplant - Rejection Prophylaxis, Pancreatic Cancer, Renal Cell... View more |
Prescription only
Prescribed for Neuroendocrine Carcinoma, Carcinoid Syndrome, Acromegaly. Lanreotide may also be used for purposes not listed in this medication guide. |
Related suggestions Neuroendocrine Carcinoma
Popular comparisons
|
|||||||||||||||
| More about Everolimus | More about Lanreotide | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Everolimus has an average rating of 5.6 out of 10 from a total of 29 ratings on Drugs.com. 46% of reviewers reported a positive effect, while 38% reported a negative effect. |
Lanreotide has an average rating of 8.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Side Effects | |||||||||||||||||
| Generic Availability | |||||||||||||||||
|
Lower cost generic |
Lower cost generic |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Everolimus prices |
View all Lanreotide prices |
||||||||||||||||
| Dosage Forms Available | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
| Afinitor, Afinitor Disperz, Torpenz, Zortress | Somatuline Depot | ||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | |||||||||||||||||
|
35 hours |
720 hours |
||||||||||||||||
| CSA Schedule ** View glossary of terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 533 drugs are known to interact with Everolimus:
|
A total of 158 drugs are known to interact with Lanreotide:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
|
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
March 30, 2009 |
N/A |
||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.